Advertisement

Pharmaceutisch Weekblad

, Volume 4, Issue 3, pp 89–90 | Cite as

Bioavailability of methotrexate tablets

  • J. H. Schornagel
  • M. E. A. G. van Engelen
  • D. de Vos
Short Communications

Abstract

The bioavailability of methotrexate 10 mg tablets has been determined to be 62±16%. After administration of a dose of 30 mg/m2 a maximum plasma concentration of ca. 20. 10−7 mole/l was found after ca. 1.7 h. The methotrexate plasma half-life was 2.4 h. It was concluded that the 10 mg tablet formulation at the dosage investigated is a suitable clinical methotrexate preparation.

Keywords

Public Health Internal Medicine Plasma Concentration Methotrexate Maximum Plasma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Bertino, J.R. (1981) In:Cancer and Chemotherapy 3, Antineoplastic Agents (Crooke, S.T., andA.W. Prestayko, Eds.). Academic Press, New York, 311–322; 359–375.Google Scholar
  2. Bleyer, W.A. (1978)Cancer 41, 36–51.PubMedGoogle Scholar
  3. Christophidis, N., F.J.E. Vadja, I. Lucas, W.J. Moon andW.J. Louis (1978)Brit. Med. J. 1, 298–300.Google Scholar
  4. Henderson, E.S., R.H. Adamson andV.T. Oliverio (1965)Cancer Res. 25, 1018–1024.PubMedGoogle Scholar
  5. Lankelma, J.E., E. Van Der Kleijn andE.F.S. Termond (1978) In:Applied Methods in Oncology 1, Clinical Pharmacology of Anti-Neoplastic Drugs (Pinedo, H.M., Ed.). Elsevier/North-Holland Biomedical Press, Amsterdam, 13–28.Google Scholar
  6. Mcvie, J.G. (1981) Personal communication.Google Scholar
  7. Steele, W.H., J.F.B. Stuart, J.R. Lawrence, C.A. McNeill, W.E. Sneader, B. Whiting, K.C. Calman andJ.G. Mcvie (1979)Cancer Chemotherap. Pharmacol. 3, 235–237.Google Scholar
  8. Stuart, J.F.B., K.C. Calman, J. Watters, J. Paxton, B. Whiting, J.R. Lawrence, W.H. Steele andJ.G. Mcvie (1979)Cancer Chemotherap. Pharmacol. 3, 239–241.Google Scholar
  9. Wan, S.H., D.H. Huffman, D.L. Azarnoff, R. Stephans andB. Hoogstraten (1974)Cancer Res. 34, 3487–3491.PubMedGoogle Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1982

Authors and Affiliations

  • J. H. Schornagel
    • 1
  • M. E. A. G. van Engelen
    • 2
    • 4
  • D. de Vos
    • 3
    • 4
  1. 1.Department of Internal MedicineUniversity HospitalGV UtrechtThe Netherlands
  2. 2.Department of Internal MedicineHospital AmstelveenAA AmstelveenThe Netherlands
  3. 3.Department of PharmacologySylvius LaboratoriesAL LeidenThe Netherlands
  4. 4.Pharmachemie BVCP HaarlemThe Netherlands

Personalised recommendations